> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Orphan Status for Novita Pancreatic Cancer Drug
- URL: https://www.fdaweb.com/orphan-status-for-novita-pancreatic-cancer-drug/
- Published: 2026-01-12T12:00:00.000Z
- Updated: 2026-09-14T15:30:23.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160472

FDA has granted Novita Pharmaceuticals an orphan drug designation for its experimental cancer drug NP-G2-044\. Novita says the designation covers the use of NP-G2-044 in pancreatic cancer, including in combination with immune checkpoint inhibitor therapies.

“This represents an important regulatory milestone for Novita and validates our scientific and clinical approach,” Novita CEO **Stewart Campbell** is quoted in a release as saying. He added that targeting fascin offers a novel strategy to enhance anti-tumor immune activity and potentially improve outcomes in a disease that has seen little therapeutic progress for decades.

Fascin plays a key role in tumor cell motility and metastasis, which accounts for the vast majority of cancer-related deaths. Novita says it is developing fascin inhibitors as a way to both block the spread of cancer and potentially improve responses to immuno-oncology therapies, which fail to benefit many patients.

NP-G2-044 is currently being studied in a multicenter Phase 2 trial evaluating the drug as both a monotherapy and in combination therapy in patients with advanced or metastatic solid tumors.